SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news

 

 
News in brief

US CRO contracted by FDA to answer generics safety questions

26-Sep-2012

CRO Vince & Associated Clinical Research (VACR) has won a $5m grant to conduct bioequivalence studies for the US FDA.

Under the contract, Kansas-based VACR will compare generic drugs with innovator products with the initial focus being on anti-epileptic products.

The contract research organisations (CRO)'s president Brad Vince said that: “With this contract we will seek to investigate the bioequivalence of generic products that have resulted in reports of Adverse Events to the FDA.”

He added that: “We are truly excited to partner with the FDA to help address agency concerns with product substitution issues.”

Related products